Skip to main content
. 2021 Aug 11;8(1):e000719. doi: 10.1136/bmjgast-2021-000719

Figure 3.

Figure 3

Primary outcome—estimated probabilities of gastric cancer stratified by proton pump inhibitor (PPI) use. The risks of gastric cancer diagnosed after time zero (ie, 365 days after percutaneous coronary intervention (PCI)) were higher in PPI users (HR 3.55; 95% CI 1.46 to 8.66, p=0.005). Noteworthily, four patients, all being PPI users, developed gastric cancer between 0 and 365 days after PCI, which were not considered as primary outcome, but reduced the number at risk at 365 days by 4.